• Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference

    المصدر: Nasdaq GlobeNewswire / 03 يناير 2024 07:00:00   America/Chicago

    Fort Lee, NJ, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the 42nd Annual J.P. Morgan Healthcare Conference, as follows:

    Date


    Monday, January 08, 2024
    Time


    04:30 PM - 05:10 PM PT
    Webcast Link


    https://jpmorgan.metameetings.net/events/healthcare24/sessions/50117-nuvectis-pharma-inc/webcast?gpu_only=true&kiosk=true

    About Nuvectis Pharma, Inc.

    Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule currently in a Phase 1b clinical trial investigating the activity of NXP800 as a potential treatment for platinum resistant, ARID1a-mutated ovarian carcinoma. The U.S. Food and Drug Administration (“FDA”) granted Fast Track Designation to the NXP800 development program in platinum resistant, ARID1a-mutated ovarian carcinoma, and Orphan Drug Designation for the treatment of cholangiocarcinoma. NXP900 is a novel, small molecule SRC/YES1 kinase inhibitor. The NXP900 Investigational New Drug Application has been cleared by the FDA and a Phase 1a dose escalation study is ongoing.

    Company Contact

    Ron Bentsur
    Chairman, Chief Executive Officer and President
    201-614-3151
    rbentsur@nuvectis.com

    Media Relations Contact

    Christopher M. Calabrese
    LifeSci Advisors
    Tel: 917-680-5608
    ccalabrese@lifesciadvisors.com 


    Primary Logo

شارك على،